Influence of Naive Lymphocyte Repertoire Size on Vaccination Efficancy
Influence of Naive Lymphocyte Repertoire Size on Vaccination Efficancy
批准号:
7808944
负责人:
Marc Kevin Jenkins
金额:
$45.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-27 至 2012-08-31
关键词:
AccountingAdultAnimalsAntibodiesAntibody FormationAntigensB-LymphocytesBindingBiological MarkersCD4 Positive T LymphocytesCellsComplexDetectionFluorochromeGoalsHLA-DR AntigensHealthHelper-Inducer T-LymphocyteHepatitis BHepatitis B Surface AntigensHepatitis B VirusHumanImmuneImmune responseImmunityImmunizationIndividualInfectionLabelLeadLymphocyteMajor Histocompatibility ComplexMeasuresMemoryMethodsPeptidesPopulationReagentSolutionsSubunit VaccinesSystems BiologyTestingVaccinatedVaccinationVaccinesVariantVirus Diseasesbaseimprovedinnovationmagnetic beadsnovelperipheral bloodpreventpublic health relevanceresponsetheoriestoolvaccine-induced immunity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The human immune response to infection and immunization - Profiling via modern immunological methods and systems biology. The Hepatitis B subunit vaccine induces immunity in millions of people by inducing antibodies that prevent viral infection. However, the variability in the antibody response to the Hepatitis B surface antigen (HBS) component of the vaccine in different individuals is remarkably large and some individuals fail to respond altogether. We propose that this variability provides a golden opportunity to understand the diversity of human immune responses to vaccination and identify immune response correlates. The central hypothesis of this application is that the number of naive antigen-specific B cells and/or CD4+ helper T cells in the pre-immune repertoire dictates the magnitude of the antibody response. We will test this hypothesis using an ultra sensitive method that we developed to detect HBS-specific B cells and HBS peptide-Major Histocompatibilty Complex II-specific CD4+ helper T cells in humans before and after vaccination. The goals of this proposal are to develop the reagents needed for comprehensive analysis of the HBS-specific naive T and B cells in humans and then use these tools to determine whether or not the great range in postvaccination antibody titer is explained by variations in the pre-immune repertoire. This innovative approach could provide the ultimate biomarker of vaccine response - the vaccine-specific lymphocytes themselves - and provide direction as to how the vaccine could be improved to protect all individuals.
PUBLIC HEALTH RELEVANCE: These studies are relevant because they have the potential to explain why certain people do not develop specific antibodies after receiving the Hepatitis B subunit vaccine. Our theory is that these individuals lack the relevant lymphocytes before vaccination. If this theory is correct, then these individuals should develop antibodies if vaccinated with a different Hepatitis B subunit. Therefore, these studies have the potential to predict who will not respond to this important vaccine and suggest a solution to this problem.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Detection and Activation of CD4+ T cells with Low Affinity TCRs
-
批准号:10348758
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2019
-
负责人:Marc Kevin Jenkins
-
依托单位:
Detection and Activation of CD4+ T cells with Low Affinity TCRs
-
批准号:10570243
-
项目类别:
-
资助金额:$38.32万
-
财政年份:2019
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T Cells
-
批准号:10349513
-
项目类别:
-
资助金额:$46.74万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:8430702
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:8810212
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:9022392
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Analysis of peripheral tolerance in vivo
-
批准号:8500973
-
项目类别:
-
资助金额:$14.88万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:8634713
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Protective CD4+ T cells
-
批准号:9228319
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Marc Kevin Jenkins
-
依托单位:
Analysis of peripheral tolerance in vivo
-
批准号:8308579
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2011
-
负责人:Marc Kevin Jenkins
-
依托单位:
Flow Cytometry Core
-
批准号:8308583
-
项目类别:
-
资助金额:$10.78万
-
财政年份:2011
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:8298298
-
项目类别:
-
资助金额:$37.19万
-
财政年份:2011
-
负责人:Marc Kevin Jenkins
-
依托单位:
Flow Cytometry Core
-
批准号:7166127
-
项目类别:
-
资助金额:$8.82万
-
财政年份:2006
-
负责人:Marc Kevin Jenkins
-
依托单位:
Analysis of peripheral tolerance in vivo
-
批准号:7166122
-
项目类别:
-
资助金额:$27.82万
-
财政年份:2006
-
负责人:Marc Kevin Jenkins
-
依托单位:
2006 FASEB SRC on Lymphocytes and Antibodies
-
批准号:7161177
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2006
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7111197
-
项目类别:
-
资助金额:$29.9万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7234300
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7092457
-
项目类别:
-
资助金额:$23.67万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7618271
-
项目类别:
-
资助金额:$32.04万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
Modular Subunit Vaccine for Salmonella
-
批准号:7808016
-
项目类别:
-
资助金额:$31.72万
-
财政年份:2005
-
负责人:Marc Kevin Jenkins
-
依托单位:
海外基金